Hello, I have made several changes to the paper, kindly utilize this upload, review, and get back in case of a concern.
Hepatitis C is a viral disorder that inflames the liver, sometimes causing grievous liver
injury. Millman et al. (2017) presume that the "hepatitis C virus" (HCV) infection is a top cause
of hepatic-associated demise, hepatocellular carcinoma, and cirrhosis. The disorder is curable,
and patients normally receive antiviral formulations to lower the virus from the body with a goal
to achieve “sustained virologic response” at least twelve weeks after completion of the treatment.
Nevertheless, the formulations used are costly, and not all health insurance schemes cater for all
prescribed formulation for hepatitis C treatment, thereby posing a treatment barrier. According to
Millman et al. (2017), restrictive directions on access to new, curative, hepatitis C formulation
constitute a considerable challenge to managing infected persons.
Avenues to Help Patients Overcome Cost Barriers
Since curing HCV provides an enduring, substantial health advantage, including lowering
the number of cases of liver carcinoma (Tenner, Melhado, Bobadilla, Turner, & Morgan, 2019),
addressing the cost hurdles encountered by infected persons is imperative. Despite the high cost
of treatment, pharmaceutical firms have a “patient assistance program” (PAP) to aid uninsured
persons to cater for all or part of the costs of the medication. The article obtained in this
exploration is the “pharmaceutical company patient assistance and cost-sharing assistance
programs: hepatitis” (NASTAD, 2017). A PAP runs through pharmaceutical firms to give lowcost or free treatment to persons tha...
15 Million Students Helped!
Sign up to view the full answer